Jubilant Ingrevia (JUBLINGR) reported ~Rs2bn EBITDA (up 40% y/y and 22% q/q) in Q1FY27, ahead of estimates, driven by strong pricing growth across Nutrition and Health Solutions (NHS) and Chemical Intermediates (CI).